These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 8471420)

  • 81. Incorporation of thymidine and iododeoxyuridine into the DNA of mouse tissues.
    Myers DK; Feinendegen LE
    Can J Physiol Pharmacol; 1975 Dec; 53(6):1014-22. PubMed ID: 1222371
    [TBL] [Abstract][Full Text] [Related]  

  • 82. DNA turnover and thymidine re-utilization in mouse tissues.
    Myers DK; Feinendegen LE
    Cell Tissue Kinet; 1976 May; 9(3):215-21. PubMed ID: 1268906
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Growth and inhibition of mouse or human tumors in "nude" (athymic) mice monitored by the extent of 125 I-5-Iodo-2'-deoxyuridine(125-IUdR) uptake.
    Merletti PR; Giovanella B; Bonmassar E; Goldin A
    Eur J Cancer (1965); 1978 Oct; 14(10):1057-64. PubMed ID: 710476
    [No Abstract]   [Full Text] [Related]  

  • 84. Conversion of 5-iodo-2-pyrimidinone-2'-deoxyribose to 5-iodo-deoxyuridine by aldehyde oxidase. Implication in hepatotropic drug design.
    Chang CN; Doong SL; Cheng YC
    Biochem Pharmacol; 1992 May; 43(10):2269-73. PubMed ID: 1599512
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Augmentation of hydroxyurea cytotoxicity by sintamil in human chronic myeloid leukemia cells.
    Pradhan SG; Chitnis MP; Basrur VS; Satyamoorthy K; Advani SH
    Tumori; 1986 Oct; 72(5):507-10. PubMed ID: 3467512
    [TBL] [Abstract][Full Text] [Related]  

  • 86. 125IUDR labelling efficiency and cytotoxicity for murine tumours in vivo and in vitro.
    Hagmar B; Ryd W
    Eur J Nucl Med; 1982; 7(3):108-14. PubMed ID: 7067712
    [TBL] [Abstract][Full Text] [Related]  

  • 87. The nature of the embryo-protective interaction of propyl gallate with hydroxyurea.
    DeSesso JM; Goeringer GC
    Reprod Toxicol; 1990; 4(2):145-52. PubMed ID: 2136029
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Instantaneous preparation of radiolabeled 5-iodo-2'-deoxyuridine.
    Foulon CF; Zhang YZ; Adelstein SJ; Kassis AI
    Appl Radiat Isot; 1995 Oct; 46(10):1039-46. PubMed ID: 7496371
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Reversed-role chemotherapy for resistant cancer.
    Bagshawe KD
    Lancet; 1986 Oct; 2(8510):778-81. PubMed ID: 2876236
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Potential for tumor therapy with iodine-125 labeled immunoglobulins.
    Adelstein SJ; Kassis AI; Baranowska-Kortylewicz J; van den Abbeele AD; Mariani G; Ito S
    Int J Rad Appl Instrum B; 1991; 18(1):43-4. PubMed ID: 2010304
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Modification of effects of radiation on thymidine kinase.
    Hohn-Elkarim K; Mühlensiepen H; Altman KI; Feinendegen LE
    Int J Radiat Biol; 1990 Jul; 58(1):97-110. PubMed ID: 1973443
    [TBL] [Abstract][Full Text] [Related]  

  • 92. On the safety of 5-[125I]iodo-2'-deoxyuridine--Preclinical evaluation in swine.
    Baranowska-Kortylewicz J; Dalrymple GV; Harrison KA; Holdeman KP; Sharp JG; Cohen SM; Lieberman RP; Schneiderman MH; Clausen SR; Hoffman D; Lai J; Schneiderman GS; Helseth L
    Acta Oncol; 1996; 35(7):925-33. PubMed ID: 9004773
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Effect of 3 growth control substances on foreign body sarcomagenesis: IFN, IUdR, MGBG.
    Mhic Iomhair M; Lavelle SM
    Ir J Med Sci; 1999; 168(1):42-4. PubMed ID: 10098343
    [TBL] [Abstract][Full Text] [Related]  

  • 94. The induction of transient increases in mitotic rate in murine tissues following prolonged intravenous infusions of hydroxyurea.
    Plager J
    Cell Tissue Kinet; 1975 Nov; 8(6):517-28. PubMed ID: 1201581
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Radiosynthesis and quality assurance of 5-[124I]Iodo-2'-deoxyuridine for functional PET imaging of cell proliferation.
    Guenther I; Wyer L; Knust EJ; Finn RD; Koziorowski J; Weinreich R
    Nucl Med Biol; 1998 May; 25(4):359-65. PubMed ID: 9639297
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Inaccuracy of estimations of s phase fraction by reduction in cloning efficiency with hydroxyurea or tritiated thymidine.
    Yen A; Lambek C; Clarkson B
    Cell Tissue Kinet; 1981 May; 14(3):301-8. PubMed ID: 6972258
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Strand-length measurements of normal and 5-iodo-2'-deoxyuridine-treated vaccinia virus deoxyribonucleic acid released by the Kleinschmidt method.
    McCrea JF; Lipman MB
    J Virol; 1967 Oct; 1(5):1037-44. PubMed ID: 5630227
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Pharmacokinetics of hydroxyurea in nude mice.
    Van den Berg CL; McGill JR; Kuhn JG; Walsh JT; De La Cruz PS; Davidson KK; Wahl GM; Von Hoff DD
    Anticancer Drugs; 1994 Oct; 5(5):573-8. PubMed ID: 7858290
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Effects of 60 Co gamma radiation on the distribution, catabolism and incorporation of 125 I-5-iodo-2'-deoxyuridine into intestinal and splenic deoxyribonucleic acid in mice.
    Johanson KJ
    Acta Radiol Ther Phys Biol; 1972 Dec; 11(6):556-65. PubMed ID: 4661523
    [No Abstract]   [Full Text] [Related]  

  • 100. Treatment of disseminated cancer by intravenous hydroxyurea and autogenous bone-marrow transplants: experience with 35 patients.
    Ariel IM
    J Surg Oncol; 1975; 7(5):331-5. PubMed ID: 1100913
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.